541502-14-1

Siltuximab it is used for cancer treatment using anti-ICOS antibody if patient has low peripheral T cell receptor clonality.

Chimeric (human-murine) immunoglobulin G1κ (IgG1κ) monoclonal antibody:
Treatment of multicentric Castleman’s disease (MCD)

Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Ciclosporin and tacrolimus: monitor levels on
initiation and discontinuation of siltuximab as it may reduce the activity of CYP450.

As siltuximab is a monoclonal antibody, the expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptormediated clearance.